EGFR and non-small cell lung carcinoma: Using the referenced data inputs, it was estimated that 2.4% (n = 1051 FP, 371 FN) of 60,502 patients in the US with newly diagnosed metastatic NSCLC and tested for EGFR mutation would be misclassified if all patients were tested with LDTs compared to 1% (n = 353 FP, 224 FN) of patients if the same cohort was tested using the FDA-approved cobas EGFR Mutation Test.